BioCina and NovaCina forge strategic alliance to offer biologics developers integrated drug substance and drug product solutions

BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, announced a strategic partnership to provide integrated drug substance and drug product solutions for biologics developers.

This alliance enables BioCina to offer the highest quality fill-and-finish solutions to their clients, to convert the drug substance produced at its state-of-the-art Adelaide, South Australia facility into ready-to-use drug product at NovaCina’s advanced facility in Perth, Australia. This collaboration marks a significant milestone in providing end-to-end biopharmaceutical manufacturing solutions to clients worldwide.

BioCina delivers highest quality, cost-effective CDMO services, including cell line development, process development, and cGMP drug substance manufacturing for the microbial, pDNA and mRNA modalities. As a result of this partnership, BioCina’s clients can benefit from NovaCina’s decades of clinical and commercial fill-and-finish experience, backed by numerous regulatory approvals, including from the U.S. Food and Drug Administration (FDA). NovaCina offers a comprehensive suite of services, including development, manufacturing, packaging, labeling, and stability studies.

BioCina Chief Executive Officer & member of NovaCina Board of Directors, Mark W. Womack said, “BioCina is excited to partner with NovaCina, integrating our globally recognized expertise in clinical and commercial process development and drug substance manufacturing with their esteemed drug product services. This partnership promises to deliver unparalleled quality, adherence to the highest regulatory standards, and on-time delivery of client programs, setting a new benchmark in the market.”

We are very excited to form this partnership with BioCina. Together, we provide a seamless end-to-end offering. At NovaCina, we are delighted to bring our world-class quality and safety to this value-adding collaboration.”

Cyrus K. Mirsaidi, Chief Executive Officer, NovaCina

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BioCina Pty Ltd.. (2024, February 29). BioCina and NovaCina forge strategic alliance to offer biologics developers integrated drug substance and drug product solutions. News-Medical. Retrieved on October 03, 2024 from https://www.news-medical.net/news/20240229/BioCina-and-NovaCina-forge-strategic-alliance-to-offer-biologics-developers-Integrated-drug-substance-and-drug-product-solutions.aspx.

  • MLA

    BioCina Pty Ltd.. "BioCina and NovaCina forge strategic alliance to offer biologics developers integrated drug substance and drug product solutions". News-Medical. 03 October 2024. <https://www.news-medical.net/news/20240229/BioCina-and-NovaCina-forge-strategic-alliance-to-offer-biologics-developers-Integrated-drug-substance-and-drug-product-solutions.aspx>.

  • Chicago

    BioCina Pty Ltd.. "BioCina and NovaCina forge strategic alliance to offer biologics developers integrated drug substance and drug product solutions". News-Medical. https://www.news-medical.net/news/20240229/BioCina-and-NovaCina-forge-strategic-alliance-to-offer-biologics-developers-Integrated-drug-substance-and-drug-product-solutions.aspx. (accessed October 03, 2024).

  • Harvard

    BioCina Pty Ltd.. 2024. BioCina and NovaCina forge strategic alliance to offer biologics developers integrated drug substance and drug product solutions. News-Medical, viewed 03 October 2024, https://www.news-medical.net/news/20240229/BioCina-and-NovaCina-forge-strategic-alliance-to-offer-biologics-developers-Integrated-drug-substance-and-drug-product-solutions.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.